Item 7.01 Regulation FD Disclosure
On October 23, 2009, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration, in response to a request from the U.S. Centers for Disease Control and Prevention, issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients admitted to a hospital with confirmed or suspected 2009 H1N1 influenza infection. The press release is being furnished as Exhibit 99.1 and is incorporated by reference under this Item 7.01 as if fully set forth herein.
The information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit No. Description 99.1 Press release dated October 23, 2009 entitled "Emergency Use Authorization Granted for BioCryst's Peramivir"

---